naringenin has been researched along with Overweight in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Javad Hosseinzadeh-Attar, M; Mahdi Rezayat, S; Mansouri, S; Naeini, F; Namkhah, Z | 1 |
| Hosseinzadeh-Attar, MJ; Jazayeri-Tehrani, SA; Mansouri, S; Naeini, F; Namkhah, Z; Rezayat, SM; Tutunchi, H; Yaseri, M | 1 |
| Hosseinzadeh-Attar, MJ; Mansouri, S; Naeini, F; Namkhah, Z; Rezayat, SM; Tutunchi, H; Yaseri, M | 1 |
3 trial(s) available for naringenin and Overweight
| Article | Year |
|---|---|
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Topics: Dietary Supplements; Double-Blind Method; Flavanones; Humans; Iran; Lipids; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Probability | 2021 |
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Topics: Dietary Supplements; Double-Blind Method; Flavanones; Humans; Iran; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Randomized Controlled Trials as Topic | 2021 |
Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.
Topics: Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Flavanones; Heart Disease Risk Factors; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Risk Factors | 2022 |